Skip to main content

Table 2 Types of PIK3CA mutations that were detected

From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Patient Treatment category Exon 9 Exon 20
1 FAC/FEC E545K  
2 FAC/FEC   H1047R
3 FAC/FEC   H1047R
4 FAC/FEC E542K  
5 FAC/FEC E545K  
6 FAC/FEC   H1047R
7 FAC/FEC E545K  
8 FAC/FEC E545K  
9 FAC/FEC   H1047R
10 FAC/FEC E545K  
11 FAC/FEC E545K  
12 FAC/FEC E545K  
13 TFAC/TFEC Q546R  
14 TFAC/TFEC   H1047T
15 TFAC/TFEC   H1047R
16 TFAC/TFEC   H1047R
17 TFAC/TFEC   H1047R
18 TFAC/TFEC E545K  
19 TFAC/TFEC E542K  
20 TFAC/TFEC E542V  
21 TFAC/TFEC   G1049R
22 TFAC/TFEC   H1047R
23 TFAC/TFEC   H1047R
  1. Exon 1 mutations were also examined but no mutations were found. FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; TFAC, paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.